European Neuropsychopharmacology (v.16, #S1)
Brain mechanisms in pharmacological and behavioral treatment of anxiety by M Fredrikson; T Furmark (S65).
The pre-synaptic dopaminergic system before and after the onset of psychosis: initial results by O.D. Howes; S.A. Montgomery; M. Asselin; R.M. Murray; P.K. McGuire; P. Grasby (S65-S66).
The role of medial septal NMDA receptors in behavioral functions of the hippocampus in the rat by E. Elvander Tottie; T. Eriksson; B. Johansson; J. Sandin; S.O. Ögren (S62-S63).
Behavioral effects of SR 58611A, a beta-3 agonist, on experimental models of mild stress by G.M. Leggio; V. Micale; D. Consoli; C. Mazzola; F. Drago (S61-S62).
Nicotinic acetylcholine receptor (nAChR) desensitization and its relevance to physiological and behavioral functions by M. Shachar; H. Cohen; E. Heldman (S60).
Acetylsalicylic acid accelerates the antidepressant effect of fluoxetine in a rat model of depression by G. Capone; S. Alboni; C. Benatti; F. Tascedda; J.M.C. Blom; J. Mendlewicz; N. Brunello (S61).
Changes in benzodiazepine receptor binding in Dutch veterans with posttraumatic stress disorder by E. Geuze; B.N.M. van Berckel; R. Boellaard; B.D. Windhorst; G. Luurtsema; A.A. Lammertsma; E. Vermetten; H.G.M. Westenberg (S66-S67).
Association study of a functional cathechol-O-methyltransferase polymorphism and cognitive remediation in schizophrenia by M. Bosia; R. Cavallaro; S. Anselmetti; M. Bechi; F. Cocchi; S. Poletti; E. Marino (S67-S68).
Influence of serotonin transporter promoter polymorphism on brain activation during a moral valence decision task by D. Radaelli; A. Bernasconi; F. Benedetti; V. Blasi; C. Colombo; A. Falini; G. Scotti; E. Smeraldi (S70-S71).
Is controversial efficacy of SSRI in treating depression in child and adolescent related to differences in study design? by T. Usala; A. Clavenna; M. Bonati; A. Zuddas (S71-S72).
Influence of brain activity at the baseline on antidepressant response to chronotherapeutic treatments: a fMRI study by S. Dallaspezia; F. Benedetti; A. Bernasconi; V. Blasi; C. Colombo; A. Falini; D. Radaelli; G. Scotti; E. Smeraldi (S70).
Changes in brain glutamate correlate with antidepressant response to total sleep deprivation: a 3 T 1H-MRS study by A. Bernasconi; G. Calabrese; F. Benedetti; D. Radaelli; S. Dallaspezia; A. Falini; C. Colombo; M. Cadioli; G. Scotti; E. Smeraldi (S69).
Cannabis use increases body mass index in patients with psychosis by V. Mondelli; M. Di Forti; F. Saeedzadeh-Sardahaee; A. Butt; A. Miorelli; A. Mule; R. Gafoor; P. Dazzan; R.M. Murray; C.M. Pariante (S68-S69).
Age and strain-related differences in sensory-motor abilities in different mouse strains by S. Deiana; C. Harrington; G. Riedel (S59-S60).
The effect of neurotrophin receptor expression and signalling on recognition learning in the rat by A. Hennigan; A. Kelly (S58-S59).
Studying the neural changes underlying the transition from casual to compulsive drug use by M.M.J. Rijkens; L.J.M.J. Vanderschuren (S51-S52).
Prenatal stress in rats attenuates hippocampal long-term potentiation and induces deficits in synaptic plasticity by S. Salomon; Y. Nachum-Biala; Y. Bogush; M. Lineal; H. Matzner; R. Yaka; M. Weinstock (S52).
Increased activity of prefrontal pyramidal neurons after phencyclidine administration: reversal by clozapine by L. Kargieman; P. Celada; F. Artigas (S50-S51).
Cannabinoid modulation of impulsivity in rats: a novel pharmacotherapeutic approach for inhibitory control deficits? by T. Pattij; M.C.W. Janssen; I. Schepers; G. Gonzalez Cuevas; A.N.M. Schoffelmeer (S49-S50).
Evidence of a simultaneous control of serotonergic and dopaminergic neurons by the medial prefrontal cortex by P. Vázquez; P. Celada; R. Cortés; F. Artigas (S49).
Semax effects on rat behavior changes induced by chronic restraint stress by D. Vilenskiy; D. Ivanova; N. Levitskaya; L. Andreeva; A. Kamensky; N. Myasoedov (S53).
The anxiolytic effect of CRF in rat brain frontal cortex is prevented by CRF1&2 receptor antagonists by B. Zieba; T. Uchacz; H. Domin; P. Branski; M. Smialowska; A. Pilc (S53-S54).
Effects of nicotinic receptor blockade on nicotine conditioned behaviors in rats by E.S. Zakharova; O.A. Dravolina; W. Danysz; E.E. Zvartau; A.Y. Bespalov (S57).
Recognition memory in the rat is associated with increased BDNF release and ERK activation in the dentate gyrus by C. Callaghan; C. Loscher; A. Kelly (S58).
Effect of lithium on the deficit in performance of a reversal learning task induced by phencyclidine in the rat by N. Idris; B. Grayson; J.C. Neill (S56-S57).
Cannabinoid CB1 receptor blocakade affects memory capacity of dopamine D3 KO mice pre-treated with β-amyloid peptide by C. Mazzola; V. Micale; G.M. Leggio; F. Drago (S55-S56).
Abnormal social cognitive processing in 47, XXY men: implications for the study of schizophrenia by S. van Rijn; H. Swaab; A. Aleman; T. Jellema; R.S. Kahn (S54-S55).
Long term outcome of drug-resistant bipolar depression: a 9 months prospective follow-up after chronotherapeutics by A. Pontiggia; F. Benedetti; B. Barbini; M. Cigala Fulgosi; C. Colombo; S. Dallaspezia; E. Smeraldi (S72-S73).
Predictive parameters for methylphenidate use and compliance in children with attention deficit hyperactivity disorder by P. Atzori; B. Ancilletta; T. Usala; F. Danjou; A. Zuddas (S73-S74).
8-OH-DPAT in combination with galantamine decreases anxiety in old male rats with Alzheimer's type amnesia by J. Fedotova; N. Platonova (S89).
Anxiolytic and antidepressant-like activities of UFP-512, a novel selective delta opioid receptor agonist by R. Vergura; G. Balboni; B. Spagnolo; E.C. Gavioli; D.G. Lambert; J. McDonald; C. Trapella; D. Regoli; S. Salvadori; G. Calo (S89-S90).
Possible genetic implications of the endocannabinoid system in anxiety disorders versus depressive disorders by A. Erhardt; P.G. Unschuld; S. Lucae; M. Ising; D. Salyakina; B. Pütz; B. Müller-Myhsok; E.B. Binder; F. Holsboer; M.E. Keck (S88).
Benzodiazepines vs. combination of benzodiazepines and SSRI in treatment of panic disorder with agoraphobia by M. Latas (S87-S88).
Anxiolytic-like effects of group III mGluR positive modulator PHCCC and agonist ACPT-I injected to the rat hippocampus by K. Stachowicz; E. Chojnacka-Wójcik; K. Klak; A. Pilc (S86-S87).
In search of the anxiolytic effects of nicotinic receptor ligands by M. Krawczyk; P. Popik (S90-S91).
Molecular dissection of the role of GABAB1 receptor isoforms 1a and 1b in anxiety-related behaviour by L.H. Jacobson; H.C. Neijt; B. Bettler; K. Kaupmann; J.F. Cryan (S91-S92).
Author index (S95-S98).
Keyword index (S99-S100).
Panic attacks are more likely to include autonomic symptoms in patients with hypertension than in normotensives — a comparison of symptoms, and factor analysis by S. Davies; P.R. Jackson; G. Lewis; S. Hood; D.J. Nutt (S94).
Anxiogenic drug treatment increases serotonin metabolism in specific anxiety-related forebrain circuits by A.K. Evans; J.K. Abrams; J.A. Bouwknecht; D.M. Knight; C.A. Lowry; A. Shekhar (S93).
Anxiety as a consequence of hypokinesia and its correction by afobazole by K. Ashrafyan; M. Balasanyan (S92-S93).
Modelling anxiety disorders in human volunteers by D.J. Nutt (S86).
New drug targets for anxiety by J. Hagan (S85).
Childhood adversity is associated with reduced central dopamine sensitivity later in life by A.F.A. Schellekens; R.J. Verkes; B. Ellenbroek; C.A.J. de Jong; J.K. Buitelaar (S77).
Postnatal handling prevents abnormalities in behaviour and memory induced by prenatal stress by Y. Nachum-Biala; S. Salomon; M. Weinstock (S78).
Basal ganglia in schizophrenia: a diffusion weighted imaging study by A. Versace; M. Tansella; N. Andreone; R. Cerini; L. Pellizza; G. Rambaldelli; G. Marrella; P. Brambilla (S76).
SNPs in FKBP5 determine a novel subtype of depression characterized by rapid response to antidepressant treatment by E.B. Binder; S. Lucae; D. Salyakina; P. Lichtner; T. Meitinger; B. Bondy; G. Wochnik; T. Rein; F. Holsboer; B. Müller-Myhsok (S75).
Divalproex sodium vs. placebo for the treatment of child and adolescent autism by E. Anagnostou; L. Soorya; E. Swanson; J. Rusoff; W. Chaplin; S. Wasserman; E. Hollander (S74-S75).
Progressive brain volume changes in first-episode psychosis: a five-year follow-up study by M. Rais; W. Cahn; N.E.M. van Haren; H.E. Hulshoff Pol; E. Caspers; H.G. Schnack; R.S. Kahn (S78-S79).
Single or low dose of ecstasy, is it safe? A prospective study on neurotoxicity of ecstasy in new ecstasy users by M.M.L. de Win; G. Jager; L. Reneman; C. Lavini; W. van den Brink; G.J. den Heeten (S79-S80).
Predictive factors of resistance to antidepressants in bipolar depression: results from a European multicentre study by P. Oswald; D. Souery; S. Kasper; Y. Lecrubier; S.A. Montgomery; J. Zohar; J. Mendlewicz (S83).
Prolactin elevation of the antipsychotic risperidone is predominantly related to its 9-hydroxy metabolite by K. Melkersson (S84).
An open-label trial of escitalopram in the treatment of impulsive-compulsive internet usage disorder by B. Dell' Osso; A.C. Altamura; S.J. Hadley; B.R. Baker; E. Hollander (S82-S83).
The effects of exertion and high levels of lactate in a 35% CO2 challenge in patients with panic disorder by G. Esquivel; C. Berlanga-Cisneros; C. Lara-Muñoz; E. Griez (S81-S82).
Specific effects of ecstasy on memory: a new approach to investigate neurotoxic effects in poly-substance ecstasy users by G. Jager; M.M.L. de Win; I. van der Tweel; R.S. Kahn; J.M. van Ree; W. van den Brink; N.F. Ramsey (S80-S81).
Effects of T3 and fluoxetine in the novelty-suppressed feeding test model of depression and anxiety: gender differences by G. Shalom; T. Lifschytz; B. Lerer; M.E. Newman (S48-S49).
Depression co-morbid with Alzheimer's disease: the role of stress factors by E. Ponomareva (S47-S48).
Possible convergence of norepinephrine and glucocorticoids signaling pathways: relevance to depression and its treatment by S.P. Yaniv; D. Ben-Shachar; E. Klein (S15-S16).
Potential molecular interactions between the histamine H3 receptor and the dopamine D2 receptor in the rat striatum by M. Humbert-Claude; S. Morisset; F. Gbahou; J.M. Arrang (S16-S17).
Neural stem cell proliferation is significantly reduced in schizophrenia, but not in depression or bipolar disorder by S. Fritzen; A. Strobel; A. Schmitt; K.P. Lesch; A. Reif (S14-S15).
Lithium inhibits stimulated striatal abundant adenylyl cyclase type V by L. Mann; G. Shaltiel; E. Heldman; R.H. Belmaker; G. Agam (S14).
Identification and functional assessment of small peptides antagonists of brain-derived neurotrophic factor (BDNF) by M. Cazorla; C. Rose; C. Pilon; J.M. Arrang; P. Sokoloff (S12-S13).
Lithium effects on basal and stimulated CREB phosphorylation in SH-SY5Y cells: a bimodal action on CaMKIV and Erk1/2 by D. Tardito; I. Pelizzoni; A. Soncin; J. Kasahara; G. Racagni; M. Popoli (S13-S14).
Role of dopamine and NMDA receptor subunits in the induction of long term potentiation in the nucleus accumbens by S.M. Schotanus; K. Chergui (S17).
TRP channel activation via tyrosine kinases as a novel antidepressant mechanism of action — studies with hyperforin by K. Treiber; A. Singer; B. Henke; W.E. Müller (S18).
Polymorphic variants in the transcriptional control region of TPH2 are preferentially transmitted in ADHD by T. Renner; S. Walitza; A. Dempfle; K. Konrad; Ch. Wewetzer; A. Halbach; B. Herpertz-Dahlmann; H. Remschmidt; J. Smidt; M. Linder; L. Flierl; U. Knölker; S. Friedel; H. Schäfer; C. Gross; J. Hebebrand; A. Warnke; K.P. Lesch (S21-S22).
Analysis of prolyl oligopeptidase (PO) as a target for bipolar disorder — characterisation of PO null-mutant mice by E. Di Daniel; A.S. Mudge; P.R. Maycox (S22-S23).
Functional proteomic analysis of an animal model of depression combining genetic vulnerability and environmental stress by A. Mallei; R. Giambelli; V.S. Barbiero; M. Maglione; A.A. Mathè; A. El Khoury; L. Carboni; E. Domenici; G. Racagni; M. Popoli (S20-S21).
Biomarker discovery in cerebrospinal fluid of depressed patients by C. Ditzen; N. Tang; A. Jacob; M. Uhr; C. Miller; C.W. Turck (S19-S20).
Vagus nerve stimulation increases neurotrophins gene expression and alters cell proliferation in the rat hippocampus by P. Follesa; F. Biggio; S. Caria; G. Gorini; F. Marrosu; G. Biggio (S18-S19).
GABAB receptor positive modulation attenuates selected molecular markers relevant to cocaine and nicotine dependence by L. Lhuillier; C. Mombereau; J.F. Cryan; K. Kaupmann (S11-S12).
Differential accumulation of cortisol and corticosterone in the murine brain by B. Mason; C.M. Pariante; L. Sanderson; S.A. Thomas (S10-S11).
Impact of prenatal dexamethasone on proliferation, migration and survival of cortical cells by A. Przyborowska; K. Fijal; K. Wedzony (S3-S4).
Fluorescence in vitro studies of human dopamine d1 and d2 receptor proteins interaction by A. Faron-Gorecka; J. Andrecka; M. Dziedzicka-Wasylewska; Z. Wasylewski (S4-S5).
Monoamine oxidase activity predicts aggressive behaviour and type II alcoholism in rhesus monkeys by H. Wargelius; C. Fahlke; L. Oreland; J.D. Higley (S3).
Chronic mild stress induces depressive behaviors: role for AMPA receptors and brain-derived neurotrophic factor by E. Toth; R. Gersner; D. Dar; I. Akirav; A. Zangen (S2).
Using mutational studies to determine the role of neurotransmitters in development by K.P. Lesch (S1-S2).
ERK 1/2 and CaMKII: two novel targets for antipsychotic therapy? by A. Frasca; F. Fumagalli; G. Racagni; M.A. Riva (S5).
Autism candidate genes in cytogenetic regions of interest identified with a gene interaction network by W. Staal; L. Franke; J.A.S. Vorstman; H. van Engeland; C. Wijminga (S6).
Association analysis of limbic system-associated membrane protein gene polymorphisms in mood and anxiety disorders by K. Koido; S. Kõks; A. Must; A. Reimets; E. Maron; J. Shlik; V. Vasar; E. Vasar (S9).
Decreased D-serine levels in CSF of schizophrenia patients by S. Amar; I. Bendikov; C. Nadri; R.A. Panizzutti; J. De Miranda; H. Wolosker; G. Agam (S10).
Effect of repeated cocaine administration on the mRNAs expression of main classes of G alpha proteins in the rat brain by A. Zelek-Molik; G. Kreiner; A. Roman; A. Bielawski; I. Nalepa (S8-S9).
Correlations between serum orexins A and B and ghrelin and BMI in anorexia nervosa by M. Janas-Kozik; I. Krupka-Matuszczyk; M. Krzystanek (S7-S8).
Combination of deferoxamine and lamotrigine in a rat model of hypoxic-ischemic brain damage by G. Papazisis; D. Kouvelas; K. Kallaras; A. Kaiki-Astara; O. Guiba-Tziampiri (S6-S7).
Chronic desipramine treatment suppresses cortical BDNF expression and ERK phosphorylation by J.B. O' Sullivan; L. Coleman; N.T. Boyle; T.J. Connor (S23).
Dopamine D2 and D3 receptor gene polymorphisms and clinical outcome of risperidone therapy in schizophrenic patients by A. Gunes; M.G. Scordo; E. Spina; M.L. Dahl (S24).
Long lasting effects of anti-depressants on olfactory bulbectomy induced hyperactivity in the open field by M.E. Breuer; L. Groenink; R.S. Oosting; B. Olivier (S39-S40).
Strain differences in the effects of GABAA receptor subtype selective compounds in the mouse light-dark test by L. Mathiasen; N.R. Mirza; R.J. Rodgers (S40-S41).
Explaining birth seasonality in fall-winter depression: idiosyncratic procreational patterns in the patients' parents by E. Pjrek; D. Winkler; A. Konstantinidis; J. Stastny; M. Willeit; N. Praschak-Rieder; S. Kasper (S39).
Animal models of human behaviour: can they help in understanding pathology and in drug development? by R.J. Rodgers (S37-S39).
Social neuroscience: from genes to social behavior by T. Insel (S37).
Comparative effects of PYY3–36, CCK-8S and sibutramine on food intake, feeding behaviour and weight gain in rats by P. Holch; R.J. Rodgers (S41-S42).
Behavioral and biochemical effects of single dose of desipramine are time-dependent by M. Kusmider; A. Faron-Gorecka; M. Dziedzicka-Wasylewska (S42-S43).
On the role of serotonin 1B (5-HT1B) receptors in cocaine- or food-maintained behaviour in rats by A. Golda; M. Filip; E. Przegaliński (S45-S46).
Clozapine application in prefrontal cortex blocks the effects of systemic MK-801 on extracellular 5-HT and glutamate by X. López-Gil; Z. Babot; M. Amargós-Bosch; C. Suñol; F. Artigas; A. Adell (S46-S47).
Withdrawal from cocaine self-administration or chronic mild stress increases immobility in the forced swim test in rats by M. Frankowska; M. Filip; M. Papp; E. Przegaliński (S45).
Effect of antidepressant drugs in mice lacking the norepinephrine transporter by E. Drozdowska; A. Faron-Gorecka; M. Kusmider; Z. Rogoz; J. Siwanowicz; M.G. Caron; H. Bonisch; M. Dziedzicka-Wasylewska (S44).
Search for the pharmacotherapy of nicotine addiction: focus on the nicotinic receptor subtypes and cannabinoid system by M. Zaniewska; A.C. McCreary; M. Filip; E. Przegaliński (S43-S44).
Genetic association data from GENDEP, a multicentre European study by P. Huezo-Diaz; M. Nash; F. Hoda; R. Williamson; P. McGuffin; I. Craig; K.J. Aitchison (S35-S36).
Allosteric changes of the NMDA receptor trap diffusible dopamine 1 receptors in spines by L. Scott; S. Zelenin; S. Malmersjö; J.M. Kowalewski; E. Zettergren-Markus; A.C. Nairn; P. Greengard; H. Brismar; A. Aperia (S34-S35).
Noradrenaline stimulates production of interleukin-1 receptor antagonist in glial cells in via B2-adrenoceptor activation by E.N. McNamee; T.J. Connor (S27-S28).
RIC-3, an effector of nAChR activity: structure, function, quantity, and regulation by Y. Biala; M. Treinin (S28).
Molecular mechanisms of cannabinoid-induced neurotoxicity in rat cortical neurons by A.M. Gowran; V.A. Campbell (S26-S27).
MDMA (“ECSTASY”) suppresses innate IFN-gamma production and signalling, and inhibits MHC II expression on APCs by N.T. Boyle; T.J. Connor (S25-S26).
Glucocorticoid sensitivity in whole blood cells from healthy volunteers: effect of antidepressants by L. Oarvalho; M.F. Juruena; A. Papadopoulos; L. Poon; R. Kerwin; C.M. Pariante (S24-S25).
Hypothalamic-pituitary-adrenocortical axis changes in male Sprague-Dawley rats after long-term voluntary exercise by S.K. Droste; Y. Chandramohan; J.M.H.M. Reul (S28-S29).
Augmentation of antidepressant response by atypical antipsychotic drugs: electrophysiological studies in the rat brain by E. Dremencov; M. El Mansari; P. Blier (S29-S30).
CYP2D6 variants and ecstasy-induced changes in neurohypophysial hormones by E. Tsapakis; K. Wolff; A.R. Winstock; P. Huezo-Diaz; C.M. Pariante; D. Hartley; D. Holt; M.L. Forsling; K.J. Aitchison (S33).
Effects of acute stress on brain-derived neurotrophic factor in the hippocampus of transgenic mouse model of depression by S. Alboni; J.M.C. Blom; D. Corsini; C. Benatti; G. Capone; C. Ferraguti; N. Barden; F. Tascedda; N. Brunello (S33-S34).
Relative expression of tryptophan hydroxylase 1 and 2 in the brain: spatial and temporal analysis by L. Gutknecht; C. Kriegebaum; A. Schmitt; K.P. Lesch (S32).
Potentiating antidepressant strategy: focus on NK1 receptor antagonists by B.P. Guiard; A.M. Gardier; P. Blier (S31-S32).
Inhibition of glycine uptake augments risperidone's effect on prefrontal glutamatergic transmission by A. Konradsson; M.M. Marcus; P. Hertel; T.H. Svensson; K.E. Jardemark (S30-S31).
GABAergic regulation of anxiety, memory and sensory perception by H. Möhler (S1).